Brandy Stewart
Family · Kingston Springs, TNNPI 1801017116
Payments from drug & device makers
Across 361 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$932
- Novo Nordisk$896
- Lilly USA, LLC$523
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$363
- Abbott$218
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,268100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $1,009 |
| AstraZeneca | 45 | $932 |
| Novo Nordisk | 53 | $896 |
| Lilly USA, LLC | 37 | $523 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $363 |
| Abbott | 12 | $218 |
| Exact Sciences | 12 | $214 |
| Boehringer Ingelheim | 12 | $206 |
| Johnson & Johnson | 12 | $192 |
| GSK | 11 | $174 |
| Astellas Pharma US Inc | 6 | $146 |
| Sumitomo Pharma America, Inc. | 8 | $140 |
| Otsuka America Pharmaceutical, Inc. | 5 | $137 |
| Pfizer | 7 | $107 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $94 |
| Teva Pharmaceuticals USA, Inc. | 3 | $82 |
| Amgen | 4 | $78 |
| Scilex Pharmaceuticals Inc. | 4 | $73 |
| Merck | 4 | $67 |
| Dexcom, Inc. | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Gilead | 3 | $51 |
| Verona Pharma, Inc. | 2 | $49 |
| Eisai Inc. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Bayer | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| Medtronic | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$6,268 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $37,322 |
| OzempicSemaglutide | 38 | $34,745 |
| TrulicityDulaglutide | 27 | $28,865 |
| EliquisApixaban | 27 | $26,044 |
| XareltoRivaroxaban | 24 | $24,812 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $23,013 |
| JardianceEmpagliflozin | 21 | $16,836 |
| FarxigaDapagliflozin Propanediol | 14 | $10,177 |
| Repatha SureclickEvolocumab | 18 | $10,009 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,777 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 244 | $5,784 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 183 | $5,426 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 191 | $5,178 |
| Pantoprazole Sodium | 247 | $3,723 |
| Gabapentin | 301 | $3,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $174 | $45,09951 claims |
| Novo NordiskOzempic | $896 | $34,74538 claims |
| PfizerEliquis, Premarin | $107 | $29,65041 claims |
| Lilly USA, LLCTrulicity | $523 | $28,86527 claims |
| Johnson & JohnsonXarelto | $192 | $24,81224 claims |
| Boehringer IngelheimJardiance | $206 | $16,83621 claims |
| AstraZenecaFarxiga | $932 | $10,17714 claims |
| AbbVieSynthroid | $1,009 | $1,67818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Kingston Springs
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.